<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Jampol, Lee M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Anti-VEGF Agents: Changing the Treatment Landscape for Diabetic Retinopathy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-24</style></pages><abstract><style  face="normal" font="default" size="100%">This article provides an update on some key trials conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), including important contributions from Protocol I. This study showed that anti-vascular endothelial growth factor (VEGF) therapy as an initial strategy should be the gold standard of treatment for diabetic macular edema.</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>